A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.

Trial Details

NCT ID
NCT07003074
Phase
PHASE3
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • TQB2102 for Injection
  • Docetaxel combined + Trastuzumab +Pertuzumab
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Lanzhou, Gansu, China|36.05701,103.83987

Key Eligibility Criteria

  • Subjects voluntarily enrolled in this study with good compliance
  • Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1
  • HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology
  • Defined hormone receptor (HR) status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →